Abstracts tagged "skin"

Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 1802 • ACR Convergence 2020
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Ileannette Robledo-Vega¹, John Scheinuk², Emmanuel Pardo², Ansley Pratt², Soham Mahato³, Andrew G. Chapple² and Myriam Guevara⁴, ¹Louisiana State University Health Sciences Center, New Orlenas, LA, ²Louisiana State University, New Orleans, LA, ³LSUHSC School of Public Health, New Orleans, LA, ⁴Lousiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
Abstract Number: 0283 • ACR Convergence 2020
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Grace Hile¹, Patrick Coit¹, Chang Zeng¹, Rachael Wasikowski², Alex Tsoi², Allison Billi², Johann Gudjonsson³, Amr Sawalha⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann ARbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴University of Pittsburgh, Pittsburgh, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…
Abstract Number: 1906 • ACR Convergence 2020
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
Hana Storkanova¹, Lenka Storkanova², Sabina Oreska³, Maja Spiritovic⁴, Barbora Hermankova⁵, Radim Becvar¹, Karel Pavelka⁶, Jiří Vencovský⁶, Jörg HW Distler⁷, Ladislav Šenolt⁶ and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
Abstract Number: 0284 • ACR Convergence 2020
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
Gantsetseg Tumurkhuu¹, Shuang Chen², Erica Montano¹, Malcolm Lane², Michifumi Yamashita², Janet Markman², Luz Blanco³, Mariana Kaplan⁴, Kenichi Shimada², Timothy Crother², Mariko Ishimori², Daniel J Wallace¹, Caroline Jefferies⁵ and Moshe Arditi², ¹Cedars-Sinai Medical Center, Los Angeles, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…
Abstract Number: 0318 • ACR Convergence 2020
Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease
Roxana Coras¹, Arthur Kavanaugh², Angela Kluzniak³, Dustina Holt³, Amy Weilgosz³, Oswald Quehenberger¹, Christopher Ritchlin⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³University of Rochester Medical Center, New York, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA), a systemic inflammatory disease, occurs in about 25% of patients with psoriasis (PsO). At present, there are no biomarkers that reliably…
Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2716 • 2018 ACR/ARHP Annual Meeting
A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
Stefanie Friedrich^1,2, Susanne Lueders³, Gerd R. Burmester⁴, Gabriela Riemekasten⁵ and Sarah Ohrndorf⁴, ¹Department of of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin; Germany, Berlin, Germany, ²Department of Radiology, Charité University Hospital, Berlin; Germany, Berlin, Germany, ³Department of Gastroenterology and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Ischemic complications such as digital ulcers (DU) are a common complication in systemic sclerosis (SSc) patients. The aim of this study was to combine…
Abstract Number: 2682 • 2017 ACR/ARHP Annual Meeting
Correlation between Capillaroscopic Patterns of Nailfold Microangiopathy and Three Different Methods to Assess Dermal Thickness in Systemic Sclerosis Patients
Barbara Ruaro¹, Alberto Sulli², Carmen Pizzorni¹, Elisa Alessandri¹, Sabrina Paolino¹, Massimo Ghio¹, Veronica Tomatis³, Vanessa Smith⁴ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Faculty of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is characterized by increase of dermal thickness (DT) and impairment of microvascular system (1). Several studies demonstrate that nailfold capillaroscopy (NVC)…
Abstract Number: 3176 • 2016 ACR/ARHP Annual Meeting
Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies
Jaclyn N. Taroni¹, Viktor Martyanov² and Michael L. Whitfield², ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Clinical trials in SSc have tended to be underpowered and not meet clinical endpoints. Genome-wide gene expression measured in some studies can prove challenging…
Abstract Number: 844 • 2015 ACR/ARHP Annual Meeting
Identification of Subclinical Skin Involvement By High Frequency Ultrasound in Systemic Sclerosis Patients
Barbara Ruaro, Alberto Sulli, Elena Bernero, Marco A. Cimmino, Sabrina Paolino and Maurizio Cutolo, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Skin involvement may be evaluated in systemic sclerosis (SSc) by modified Rodnan skin score (mRSS), the validated method to distinguish between patients with limited…
Abstract Number: 2777 • 2014 ACR/ARHP Annual Meeting
Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients
Marie Jachiet¹, Alain Le Quellec², Alban Deroux³, Pascal Godmer⁴, Mikael Ebbo⁵, Leonardo Astudillo⁶, Beatrice Flageul⁷, Nicolas Dupin⁸, Selim Aractingi¹, Loïc Guillevin for the French Vasculitis Study Group⁹, Luc Mouthon⁹ and Benjamin Terrier¹⁰, ¹Dermatology, Cochin Hospital, Paris, France, ²Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ⁵Internal Medicine, CHU, Marseille, France, ⁶Internal Medicine, CHU, Toulouse, France, ⁷Dermatology, Saint Louis, Paris, France, ⁸Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose Hypocomplementemic urticarial vasculitis (HUV), an uncommon vasculitis of unknown etiology, is rarely reported. It is also called anti-C1q vasculitis in the 2012 revised International…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].